Antidyslipidemics

Questions: Discounts, Updates etc.

Price: $15,200.00

Publication Date: 2005-12-23

Order Online Now

People that purchased this report also purchased:

Contact LeadDiscovery

  • If you have questions about this report
  • To find out if you qualify for a discount
  • Want a more up to date version
  • Can't find a report that meets your needs
Search all reports

Keywords:

Boolean terms AND, OR, NOT can be used. Phrases should be entered within quotes. For wildcards use an *

The antidyslipidemics market is driven by the statins, which account for 87% of it. However, as many statins are expected to face patent expiry in the coming decade their role is expected to change from a driver to that of almost a resistor. Manufacturers are looking to novel products to protect their franchise, such as Pfizer's atorvastatin/torcetrapib.


Scope

  • Country specific event-driven sales forecasts for the period 2005-14 for the US, Japan, France, Germany, Italy, Spain and the UK and Global overview
  • Patient potential and prescribing trends overview in the antidyslipidemics market, based on historical sales data and future key events
  • Profiles of the country and market-specific issues which will impact future sales, including generic erosion and class switching
  • Case studies presenting Pfizer's strategy with atorvastatin/torcetrapib to maintain the Lipitor franchise, and the impact of key clinical trials


    • Report Highlights
    Increased knowledge of the metabolic syndrome, fears of statin side effects, and the increasing data on the importance of HDL have all served to drive growth of the adjunctive anti-dyslipidemic agent market, by creating an opportunity for novel as well as combination therapies.

    Pfizer's atorvastatin + torcetrapib combination is expected to have a major impact on the dyslipidemia market and is expected to compete with both atorvastatin and Vytorin (simvastatin + ezetimibe). While AstraZeneca's Crestor is set to significantly increase in sales due to new safety data.

    The expiration of key statin patents could lead to the shrinking of the market value. The situation will be salvaged by the growing classes of cholesterol uptake inhibitors and single pill combinations.


    Reasons to Purchase

  • View independent, event-driven forecasts for key anti-dyslipidemic products and classes across the seven major markets
  • Obtain key opinion leader comments on various topics including prescribing trends and opinions on currently marketed and late stage development drugs
  • Identify the potential impact of clinical trial results, EU healthcare reform and new product launches on the antidyslipidemic market

    • Table of Contents

    Other users found this report page using the following search terms: dylipidemia cholesterol lypanthyl antidyslipidemic antidyslipidemics effects side lipanthyl market benflourex statin sales

    If you can't find a report that meets your needs contact LeadDiscovery. We are one of the few report providers with extensive drug development experience and we frequently use this knowledge to help clients source the most appropriate reports or produce reports for them from scratch.